IL3RA and CD4+/CD56+ hematodermic neoplasm: The diagnosis of BPDCN hinges on the detection of CD123 and TCF4, with an absence of lineage-specific markers such as CD3, CD19, CD64, and myeloperoxidase [28] (Figure 4).